Novartis MS drug remibrutinib cuts relapses, no liver safety signal in trials

Novartis reported positive Phase III trial results for remibrutinib, showing 31–35% reduction in MS relapses and a 29.2% reduction in disability progression. The drug demonstrated a favorable safety profile compared to teriflunomide, with lower liver enzyme elevations and fewer adverse event discontinuations. Novartis positions remibrutinib as a potential new treatment for relapsing multiple sclerosis (RMS).

Novartis reported a 19.1% reduction in death risk for early breast cancer patients treated with Kisqali (ribociclib) plus endocrine therapy, per six-year NATALEE trial data. Benefits included a 5.3% invasive disease-free survival increase and a 2.1% overall survival difference. The findings support Kisqali's role in treating high-risk early breast cancer, according to Novartis and trial investigators.

Novartis reported positive late-stage study results for its drug remibrutinib. The company held a special call to discuss the findings. Novartis shares have seen a 16.79% increase year-to-date, trading at 128.00 CHF.

Novartis' MS drug reduced relapse rates by 31.2% to 35.2% vs. teriflunomide, missing analyst expectations of 45%-60%. Roche's rival drug showed a 55% reduction. Novartis' drug showed no liver safety issues, unlike Roche's. Analysts estimate peak sales of $4B if approved. (NVS, RHHBY)

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.

Novartis' remibrutinib showed a 30% reduction in disability progression in a Phase III trial for multiple sclerosis (MS). The drug also increased the proportion of patients with no evidence of disease activity. Novartis estimates a $4B opportunity for remibrutinib in relapsing MS. The company reported no major safety differences compared to teriflunomide. Novartis is conducting additional studies, with results expected in 2028 and 2031.